[Botulinum toxin type A for preventive treatment of chronic migraines].
The use of botulinum toxin type A for chronic migraines was studied systematically in the PREEMPT trials program. Superiority to placebo treatment was established. Thus, for the first time a prophylactic drug against chronic migraines is available that is both effective and well tolerated. Botox® was licensed in England for the prophylaxis of headaches in adults with chronic migraines (headaches on at least 15 days per month of which at least 8 days are with migraines) in 2010.
Neurologisch-verhaltensmedizinische Schmerzklinik Kiel, Heikendorfer Weg 9-27, 24149, Kiel, Deutschland. hg@schmerzklinik.de
H
H
Göbel
A
A
Heinze
D000328:Adult; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D002908:Chronic Disease; D019317:Evidence-Based Medicine; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy*; D009465:Neuromuscular Agents / Q000627:therapeutic use
D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A